The physiological functions of the opioid-like receptor ORL1 have been investigated to a great extent since the discovery of its endogenous ligand, nociceptin/Orphanin FQ (N/OFQ). Although it was initially found to be nociceptive, N/OFQ has also been shown to be analgesic under certain experimental conditions. Because N/OFQ is a 17 amino acid peptide, it must be administered directly into the brain or spinal cord, and it degrades relatively quickly. More importantly, there have been no selective antagonists to define the ORL1-mediated actions of N/OFQ. To better understand the actions of N/OFQ and ORL1, a variety of methods will be used to identify compounds that modulate the activities of ORL1. Studies will also be initiated to characterize and modulate the promoter region of proN/OFQ and thus the expression of N/OFQ. These studies indirectly serve the same function, in that the activity of ORL1 will be affected. The avenues to be explored, as reflected in the Specific Aims, include several independent methods to identify non-peptide agonists and antagonists of ORL1. These methods include screening of combinatorial libraries and fungal extracts as well as standard medicinal chemistry. The physiological actions of non-peptide agonists and antagonists will be examined in vitro by their actions on [35S]GTPgammaS binding and cAMP accumulation in CHO cells transfected with ORL1, and in vivo by their effects on antinociception in mice. The promoter region of proN/OFQ will be cloned, sequenced, transfected into an expression vector, and examined to gain a better understanding of the regulation of proN/OFQ transcription. The use of combinatorial libraries or fungal extracts will also be explored to test the hypothesis that small molecules can be identified that might modulate proN/OFQ transcription. Finally, we will test the hypothesis that endogenous substances can be isolated from rat brain that might act as functional ORL1 antagonists. Each of these aims represents a step toward understanding the actions of ORL1 and N/OFQ and exploring into the usefulness of this receptor system for the production of non-addicting analgesics or other therapeutic agents.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
5R01DA006682-11
Application #
6515441
Study Section
Special Emphasis Panel (ZRG1-MDCN-5 (01))
Program Officer
Rapaka, Rao
Project Start
1990-09-30
Project End
2004-11-30
Budget Start
2002-06-01
Budget End
2004-11-30
Support Year
11
Fiscal Year
2002
Total Cost
$393,043
Indirect Cost
Name
Sri International
Department
Type
DUNS #
City
Menlo Park
State
CA
Country
United States
Zip Code
94025
Khroyan, Taline V; Polgar, Willma E; Orduna, Juan et al. (2007) Anti-nociceptive and anti-allodynic effects of a high affinity NOP hexapeptide [Ac-RY(3-Cl)YRWR-NH2] (Syn 1020) in rodents. Eur J Pharmacol 560:29-35
Zaveri, Naunihal T; Waleh, Nahid; Toll, Lawrence (2006) Regulation of the prepronociceptin gene and its effect on neuronal differentiation. Gene 384:27-36
Jong, Ling; Zaveri, Nurulain; Toll, Lawrence (2004) The design and synthesis of a novel quinolizidine template for potent opioid and opioid receptor-like (ORL1, NOP) receptor ligands. Bioorg Med Chem Lett 14:181-5
Judd, A K; Tuttle, D J; Jones, R W et al. (2004) Structure-activity studies on high affinity NOP-active hexapeptides. J Pept Res 64:87-94
Judd, A K; Kaushanskaya, A; Tuttle, D J et al. (2003) N-terminal modifications leading to peptide ORL1 partial agonists and antagonists. J Pept Res 62:191-8
Zaveri, Naunihal T; Green, Christopher J; Polgar, Willma E et al. (2002) Regulation of transcription of the human prepronociceptin gene by Sp1. Gene 290:45-52
Zaveri, N; Polgar, W E; Olsen, C M et al. (2001) Characterization of opiates, neuroleptics, and synthetic analogs at ORL1 and opioid receptors. Eur J Pharmacol 428:29-36
Zaveri, N T; Green, C J; Toll, L (2000) Transcriptional regulation of the human prepronociceptin gene. Biochem Biophys Res Commun 276:710-7
Burnside, J L; Rodriguez, L; Toll, L (2000) Species differences in the efficacy of compounds at the nociceptin receptor (ORL1). Peptides 21:1147-54
Toll, L; Polgar, W E; Auh, J S (1997) Characterization of the delta-opioid receptor found in SH-SY5Y neuroblastoma cells. Eur J Pharmacol 323:261-7

Showing the most recent 10 out of 20 publications